Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Business Officer | September 11, 2023 | September 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
Replimune Group, Inc.
Report date September 11, 2023 · Filed September 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,794 |
Reported balance
After 2023-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-11 · Exercise / conversion · Acquired 5,358 · Balance 268,794 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-09-11 · Sale · Disposed 5,358 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 263,736 |
Reported balance
After 2023-09-12 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-09-12 · Exercise / conversion · Acquired 300 · Balance 263,736 |
| Common StockSEC Table I · non-derivative | Direct | 263,436 |
Reported balance
After 2023-09-12 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-09-12 · Sale · Disposed 300 · Balance 263,436 F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,333 |
Reported balance
After 2023-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-11 · Exercise / conversion · Disposed 5,358 · Balance 86,333 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-07-26 | Direct | 86,033 |
Reported balance
After 2023-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-12 · Exercise / conversion · Disposed 300 · Balance 86,033 F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
F4: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 6,068 | $0.00 Strike: $99.87 | $0.00 |
DisclosureSEC source: 0001193125-26-283134 · ownership.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 Underlying: Common Stock · 6,068 shares Expires 2036-06-23 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $31.20 | $0.00 |
DisclosureSEC source: 0001193125-26-230730 · ownership.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,000 shares Expires 2034-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| May 19, 2026 Filed May 19, 2026 20:05 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 1,000 | $31.20 | $31,200.00 |
DisclosureSEC source: 0001193125-26-230730 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0001193125-26-118032 · ownership.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,200 | $79.94 | $95,933.04 |
DisclosureSEC source: 0001193125-26-118032 · ownership.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.73 to $80.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 600 | $79.24 | $47,546.34 |
DisclosureSEC source: 0001193125-26-118032 · ownership.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.70 to $79.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 700 | $77.71 | $54,397.77 |
DisclosureSEC source: 0001193125-26-118032 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,800 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.46 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2026 Filed Mar 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $49.10 | $122,750.00 |
DisclosureSEC source: 0001193125-26-118032 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0001193125-26-061686 · ownership.xml · derivative · entry 4 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 600 | $88.10 | $52,860.00 |
DisclosureSEC source: 0001193125-26-061686 · ownership.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.58 to $88.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,900 | $87.06 | $165,410.01 |
DisclosureSEC source: 0001193125-26-061686 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 600 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.52 to $87.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 20, 2026 Filed Feb 20, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $49.10 | $122,750.00 |
DisclosureSEC source: 0001193125-26-061686 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · derivative · entry 7 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $31.20 | $0.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 3,000 shares Expires 2034-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 200 | $68.52 | $13,704.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · nonDerivative · entry 5 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,900 | $67.99 | $333,145.12 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.47 to $68.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 400 | $66.68 | $26,672.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,100 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.40 to $66.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $49.10 | $122,750.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 3,000 | $31.20 | $93,600.00 |
DisclosureSEC source: 0001193125-26-016934 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $31.20 | $0.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · derivative · entry 10 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 3,000 shares Expires 2034-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · derivative · entry 9 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2033-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,563 | $0.00 Strike: $49.10 | $0.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · derivative · entry 8 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 12,563 shares Expires 2031-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,000 | $84.07 | $84,070.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 7 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.99 to $84.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,099 | $83.45 | $342,064.42 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 6 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,959 | $82.34 | $655,361.57 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 5 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,099 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 14,505 | $81.56 | $1,182,984.29 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,058 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.99 to $81.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 3,000 | $31.20 | $93,600.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,000 | $27.67 | $332,040.00 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 23:07 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 12,563 | $49.10 | $616,843.30 |
DisclosureSEC source: 0001193125-25-323090 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 01:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $46.47 | $0.00 |
DisclosureSEC source: 0000950170-25-090583 · ownership.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0000950170-25-081201 · ownership.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,127 Underlying: Common Stock · 5,000 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F3 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,000 | $49.04 | $245,185.50 |
DisclosureSEC source: 0000950170-25-081201 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,000 | $29.55 | $147,750.00 |
DisclosureSEC source: 0000950170-25-081201 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0000950170-24-132401 · ownership.xml · derivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,127 Underlying: Common Stock · 2,500 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,500 | $49.00 | $122,500.00 |
DisclosureSEC source: 0000950170-24-132401 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 2,500 | $29.55 | $73,875.00 |
DisclosureSEC source: 0000950170-24-132401 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $14.18 | $0.00 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,627 Underlying: Common Stock · 8,500 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,150 | $48.75 | $348,581.09 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $49.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,350 | $47.75 | $303,184.56 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,150 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.26 to $48.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 5,000 | $14.18 | $70,900.00 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. Read SEC document |
| September 17, 2024 Filed Sep 17, 2024 22:20 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 8,500 | $29.55 | $251,175.00 |
DisclosureSEC source: 0000950170-24-107458 · ownership.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 18, 2024 adopted by the reporting person. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $31.20 | $0.00 |
DisclosureSEC source: 0000950170-24-075705 · ownership.xml · derivative · entry 1 Esposito Pamela · CIK 0001744425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 300 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · derivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,033 Underlying: Common Stock · 300 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 300 | $20.00 | $6,000.00 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · nonDerivative · entry 4 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,436 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 300 | $3.30 | $990.00 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · nonDerivative · entry 3 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,358 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,333 Underlying: Common Stock · 5,358 shares Expires 2027-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,358 | $20.01 | $107,213.58 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · nonDerivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 263,436 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 5,358 | $3.30 | $17,681.40 |
DisclosureSEC source: 0001104659-23-100560 · tm2325969-1_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 25, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001104659-23-094997 · tm2324763-1_4seq1.xml · derivative · entry 5 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,750 Underlying: Common Stock · 5,000 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 75,750 shares of the Issuer's common stock on April 1, 2019. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.